Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect information on what effects (good or bad) CT-2103
(Xyotax) has on breast cancer as well as any side effects the drug may cause.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital